Japan's Astellas Pharma maintains full-year profit forecast amid overseas M&A

Japan's Astellas Pharma maintains full-year profit forecast amid overseas M&A

Japan’s Astellas Pharma Inc reiterated its fullyear operating profit forecast on Friday, as a jump in sales of its prostate cancer drug drug countered overseas acquisition costs.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter